LRMR

7.36

2.77% -0.21

Handel nachbörslich: 7.36

Larimar Therapeutics Inc (LRMR)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$7.57

Offen:

$7.49

24-Stunden-Volumen:

736.02K

Relative Volume:

1.30

Marktkapitalisierung:

$477.27M

Einnahmen:

Nettoeinkommen (Verlust:

$-36.95M

KGV:

-8.00

EPS:

-0.92

Netto-Cashflow:

$-33.46M

1W Leistung:

-5.40%

1M Leistung:

+10.68%

6M Leistung:

-5.22%

1J Leistung:

+130.36%

1-Tages-Spanne:

$7.20

$7.59

1-Wochen-Bereich:

$7.20

$8.77

52-Wochen-Spanne:

$2.18

$13.68

Larimar Therapeutics Inc Stock (LRMR) Company Profile

Firmenname

Larimar Therapeutics Inc

Sektor

Healthcare (1182)

Branche

Biotechnology (671)

Telefon

844-511-9056

Adresse

THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-12

Neueste SEC-Einreichungen

LRMR's Discussions on Twitter

Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2022-10-19	Eingeleitet	Guggenheim	Buy
2022-02-15	Herabstufung	William Blair	Outperform → Mkt Perform
2021-02-10	Eingeleitet	JMP Securities	Mkt Outperform
2021-02-01	Eingeleitet	William Blair	Outperform

Larimar Therapeutics Inc Aktie (LRMR) Neueste Nachrichten

Nov 04, 2024

What is HC Wainwright's Estimate for LRMR FY2024 Earnings? - MarketBeat

Nov 04, 2024

Nov 02, 2024

HC Wainwright Reiterates “Buy” Rating for Larimar Therapeutics (NASDAQ:LRMR) - Defense World

Nov 02, 2024

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Holdings Cut by Assenagon Asset Management S.A. - MarketBeat

Nov 02, 2024

Nov 01, 2024

Larimar Therapeutics Inc Reports Q3 2024 Net Loss of $15.5 Milli - GuruFocus.com

Nov 01, 2024

Oct 31, 2024

Larimar Therapeutics (NASDAQ:LRMR) Announces Quarterly Earnings Results, Beats Expectations By $0.13 EPS - MarketBeat

Oct 31, 2024

Larimar Therapeutics (NASDAQ:LRMR) Receives "Buy" Rating from HC Wainwright - MarketBeat

Oct 31, 2024

Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MSN

Oct 31, 2024

Larimar Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Oct 30, 2024

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results - GlobeNewswire

Oct 30, 2024

Oct 26, 2024

(LRMR) Investment Analysis and Advice - Stock Traders Daily

Oct 26, 2024

Oct 24, 2024

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Oct 24, 2024

Larimar Therapeutics (NASDAQ:LRMR) Trading Up 6.8%Here's Why - MarketBeat

Oct 24, 2024

Oct 20, 2024

Larimar Therapeutics (NASDAQ:LRMR) Now Covered by Analysts at Oppenheimer - Defense World

Oct 20, 2024

Oct 17, 2024

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth - Yahoo Finance

Oct 17, 2024

Oct 16, 2024

Larimar initiated with bullish view at Oppenheimer on lead drug - MSN

Oct 16, 2024

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock - Benzinga

Oct 16, 2024

Larimar stock gets bullish view at Oppenheimer (LRMR:NASDAQ) - Seeking Alpha

Oct 16, 2024

Oppenheimer Begins Coverage on Larimar Therapeutics (NASDAQ:LRMR) - MarketBeat

Oct 16, 2024

Oct 15, 2024

(LRMR) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Oct 15, 2024

Oct 10, 2024

Millennium Management LLC Boosts Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat

Oct 10, 2024

Oct 09, 2024